AKT1 and prostate neoplasm: Whereas a RAS mutation in other carcinomas might activate both ERK and PI3K signaling, we propose that prostate tumors have an alternative way to activate these pathways: PTEN deletion (PI3K/AKT activation) coupled with oncogenic ETS-overexpression (activation of RAS/ERK target genes).